Nitorum Capital, L.P. - HAEMONETICS CORP ownership

HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 298 filers reported holding HAEMONETICS CORP in Q1 2021. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.

Quarter-by-quarter ownership
Nitorum Capital, L.P. ownership history of HAEMONETICS CORP
ValueSharesWeighting
Q4 2020$47,749,000
+36.7%
402,100
+0.4%
1.85%
+19.6%
Q3 2020$34,931,000
-1.4%
400,352
+1.2%
1.55%
-15.2%
Q2 2020$35,433,000
-9.8%
395,635
+0.4%
1.82%
-40.0%
Q1 2020$39,272,000
+21.8%
394,064
+40.4%
3.04%
+68.6%
Q4 2019$32,239,000
-8.6%
280,586
+0.4%
1.80%
-12.0%
Q3 2019$35,257,000
-32.0%
279,510
-35.1%
2.05%
-30.5%
Q2 2019$51,844,000
+83.1%
430,810
+33.1%
2.95%
+57.4%
Q1 2019$28,315,000
+14.9%
323,677
+31.4%
1.87%
-25.6%
Q4 2018$24,637,000
+27.3%
246,248
+45.8%
2.52%
+16.4%
Q3 2018$19,356,000
-61.9%
168,929
-70.2%
2.16%
-62.0%
Q2 2018$50,830,000
-25.8%
566,789
-39.5%
5.69%
-24.4%
Q1 2018$68,499,000
+22.5%
936,296
-2.8%
7.53%
+13.3%
Q4 2017$55,921,000
+49.1%
962,827
+15.2%
6.64%
+7.1%
Q3 2017$37,495,000
+62.1%
835,634
+42.7%
6.21%
+34.9%
Q2 2017$23,132,000
+26.6%
585,760
+30.0%
4.60%
-3.7%
Q1 2017$18,276,000
+10.0%
450,484
+9.0%
4.78%
-0.0%
Q4 2016$16,608,000
+30.4%
413,122
+17.4%
4.78%
-6.8%
Q3 2016$12,740,000
+49.0%
351,833
+19.3%
5.13%
+25.7%
Q2 2016$8,550,000
+33.8%
294,922
+61.5%
4.08%
+23.4%
Q1 2016$6,388,000
+15.7%
182,610
+6.7%
3.31%
+5.6%
Q4 2015$5,520,000171,2233.13%
Other shareholders
HAEMONETICS CORP shareholders Q1 2021
NameSharesValueWeighting ↓
Iron Triangle Partners LP 330,000$36,633,0004.66%
BEACONLIGHT CAPITAL, LLC 156,395$17,361,0002.80%
Bridge City Capital, LLC 48,011$5,330,0001.77%
Summit Creek Advisors LLC 121,362$13,472,0001.61%
Sivik Global Healthcare LLC 25,000$2,775,0001.01%
ANCHOR CAPITAL ADVISORS LLC 412,218$45,760,0000.97%
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income 69,655$7,732,0000.90%
Orbimed Advisors 852,000$94,581,0000.88%
LONDON CO OF VIRGINIA 1,057,738$117,420,0000.67%
WEXFORD CAPITAL LP 40,138$4,456,0000.66%
View complete list of HAEMONETICS CORP shareholders